Anton W Langerak

List of Publications by Year
in descending order

151 papers	7,083 citations	87888 38 h-index	62596 80 g-index
155 all docs	155 docs citations	155 times ranked	7856 citing authors

#	Article	IF	Citations
1	Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. New England Journal of Medicine, 2014, 370, 1101-1110.	27.0	1,284
2	Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions. New England Journal of Medicine, 2019, 380, 2225-2236.	27.0	599
3	Stereotyped B-cell receptors in one-third of chronic lymphocytic leukemia: a molecular classification with implications for targeted therapies. Blood, 2012, 119, 4467-4475.	1.4	350
4	New insights on human T cell development by quantitative T cell receptor gene rearrangement studies and gene expression profiling. Journal of Experimental Medicine, 2005, 201, 1715-1723.	8.5	318
5	Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. Journal of Clinical Oncology, 2019, 37, 269-277.	1.6	250
6	Molecular and flow cytometric analysis of the VÎ² repertoire for clonality assessment in mature TCRÎ±Î² T-cell proliferations. Blood, 2001, 98, 165-173.	1.4	230
7	Standardized next-generation sequencing of immunoglobulin and T-cell receptor gene recombinations for MRD marker identification in acute lymphoblastic leukaemia; a EuroClonality-NGS validation study. Leukemia, 2019, 33, 2241-2253.	7.2	177
8	Flow cytometric analysis of the V? repertoire in healthy controls. Cytometry, 2000, 40, 336-345.	1.8	174
9	Immunoglobulin gene rearrangements and the pathogenesis of multiple myeloma. Blood, 2007, 110, 3112-3121.	1.4	157
10	Dynamic Risk Profiling Using Serial Tumor Biomarkers for Personalized Outcome Prediction. Cell, 2019, 178, 699-713.e19.	28.9	138
11	Whole-exome sequencing in relapsing chronic lymphocytic leukemia: clinical impact of recurrent RPS15 mutations. Blood, 2016, 127, 1007-1016.	1.4	130
12	Ig Heavy Chain Gene Rearrangements in T-Cell Acute Lymphoblastic Leukemia Exhibit Predominant Dh6-19 and Dh7-27 Gene Usage, Can Result in Complete V-D-J Rearrangements, and Are Rare in T-Cell Receptor îœ€Î² Lineage. Blood, 1999, 93, 4079-4085.	1.4	124
13	Phenotypic and functional characterization of T cells in white matter lesions of multiple sclerosis patients. Acta Neuropathologica, 2017, 134, 383-401.	7.7	121
14	Venetoclax and obinutuzumab in chronic lymphocytic leukemia. Blood, 2017, 129, 2702-2705.	1.4	108
15	Clinical effect of stereotyped B-cell receptor immunoglobulins in chronic lymphocytic leukaemia: a retrospective multicentre study. Lancet Haematology,the, 2014, 1, e74-e84.	4.6	93
16	Next-generation sequencing of immunoglobulin gene rearrangements for clonality assessment: a technical feasibility study by EuroClonality-NGS. Leukemia, 2019, 33, 2227-2240.	7.2	92
17	BIOMED-2 Multiplex Immunoglobulin/T-Cell Receptor Polymerase Chain Reaction Protocols Can Reliably Replace Southern Blot Analysis in Routine Clonality Diagnostics. Journal of Molecular Diagnostics, 2005, 7, 495-503.	2.8	85
18	Functional loss of Iº Bîµ leads to NF-Iº B deregulation in aggressive chronic lymphocytic leukemia. Journal of Experimental Medicine, 2015, 212, 833-843.	8.5	85

#	Article	IF	Citations
19	ARResT/Interrogate: an interactive immunoprofiler for IG/TR NGS data. Bioinformatics, 2017, 33, 435-437.	4.1	85
20	Molecular immunoglobulin/T- cell receptor clonality analysis in cutaneous lymphoproliferations. Experience with the BIOMED-2 standardized polymerase chain reaction protocol. Haematologica, 2003, 88, 659-70.	3.5	78
21	Pitfalls in TCR gene clonality testing: teaching cases. Journal of Hematopathology, 2008, 1, 97-109.	0.4	76
22	Monoclonal TCR-VÎ²13.1+/CD4+/NKa+/CD8â^'/+dim T-LGL lymphocytosis: evidence for an antigen-driven chronic T-cell stimulation origin. Blood, 2007, 109, 4890-4898.	1.4	72
23	Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. Blood, 2021, 137, 1365-1376.	1.4	72
24	Similar recombination-activating gene (RAG) mutations result in similar immunobiological effects but in different clinical phenotypes. Journal of Allergy and Clinical Immunology, 2014, 133, 1124-1133.e1.	2.9	71
25	Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. Blood, 2015, 125, 856-859.	1.4	70
26	Quality control and quantification in IG/TR next-generation sequencing marker identification: protocols and bioinformatic functionalities by EuroClonality-NGS. Leukemia, 2019, 33, 2254-2265.	7.2	70
27	Transcriptional Control of T Lymphocyte Differentiation. Stem Cells, 2001, 19, 165-179.	3.2	68
28	Ordered recombination of immunoglobulin light chain genes occurs at the IGK locus but seems less strict at theIGL locus. Blood, 2001, 97, 1001-1008.	1.4	65
29	Basic helix-loop-helix proteins E2A and HEB induce immature T-cell receptor rearrangements in nonlymphoid cells. Blood, 2001, 98, 2456-2465.	1.4	63
30	PID Comes Full Circle: Applications of V(D)J Recombination Excision Circles in Research, Diagnostics and Newborn Screening of Primary Immunodeficiency Disorders. Frontiers in Immunology, 2011, 2, 12.	4.8	62
31	High-Throughput Immunogenetics for Clinical and Research Applications in Immunohematology: Potential and Challenges. Journal of Immunology, 2017, 198, 3765-3774.	0.8	61
32	A model for predicting effect of treatment on progression-free survival using MRD as a surrogate end point in CLL. Blood, 2018, 131, 955-962.	1.4	61
33	Targeted next-generation sequencing in chronic lymphocytic leukemia: a high-throughput yet tailored approach will facilitate implementation in a clinical setting. Haematologica, 2015, 100, 370-376.	3.5	57
34	Different spectra of recurrent gene mutations in subsets of chronic lymphocytic leukemia harboring stereotyped B-cell receptors. Haematologica, 2016, 101, 959-967.	3.5	57
35	Multicolor Flowcytometric Immunophenotyping Is a Valuable Tool for Detection of Intraocular Lymphoma. Ophthalmology, 2013, 120, 991-996.	5.2	54
36	Loss of CD44dim Expression from Early Progenitor Cells Marks T-Cell Lineage Commitment in the Human Thymus. Frontiers in Immunology, 2017, 8, 32.	4.8	53

#	Article	IF	Citations
37	B-cell prolymphocytic leukemia: a specific subgroup of mantle cell lymphoma. Blood, 2014, 124, 412-419.	1.4	48
38	Ageing and latent CMV infection impact on maturation, differentiation and exhaustion profiles of T-cell receptor gammadelta T-cells. Scientific Reports, 2017, 7, 5509.	3.3	44
39	Bone marrow immunophenotyping by flow cytometry in refractory cytopenia of childhood. Haematologica, 2015, 100, 315-323.	3.5	38
40	Loss of juxtaposition of RAG-induced immunoglobulin DNA ends is implicated in the precursor B-cell differentiation defect in NBS patients. Blood, 2010, 115, 4770-4777.	1.4	37
41	Comprehensive translocation and clonality detection in lymphoproliferative disorders by next-generation sequencing. Haematologica, 2017, 102, e57-e60.	3.5	35
42	Immunoglobulin/T-cell receptor clonality diagnostics. Expert Opinion on Medical Diagnostics, 2007, 1, 451-461.	1.6	34
43	Development of a diverse human T-cell repertoire despite stringent restriction of hematopoietic clonality in the thymus. Proceedings of the National Academy of Sciences of the United States of America, 2015, 112, E6020-7.	7.1	34
44	Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: the 2022 update of the recommendations by ERIC, the European Research Initiative on CLL. Leukemia, 2022, 36, 1961-1968.	7.2	34
45	Multiple clonal Ig/TCR products: implications for interpretation of clonality findings. Journal of Hematopathology, 2012, 5, 35-43.	0.4	33
46	Molecular discrimination between relapsed and secondary acute lymphoblastic leukemia: Proposal for an easy strategy. Medical and Pediatric Oncology, 2001, 36, 352-358.	1.0	32
47	Prognostic value of MRD in CLL patients with comorbidities receiving chlorambucil plus obinutuzumab or rituximab. Blood, 2019, 133, 494-497.	1.4	32
48	Next-Generation Sequencing Analysis of the Human TCRÎ³Î´+ T-Cell Repertoire Reveals Shifts in VÎ³- and VÎ´-Usage in Memory Populations upon Aging. Frontiers in Immunology, 2018, 9, 448.	4.8	31
49	Immunoglobulin gene analysis in chronic lymphocytic leukemia in the era of next generation sequencing. Leukemia, 2020, 34, 2545-2551.	7.2	29
50	Unraveling the Consecutive Recombination Events in the HumanIGKLocus. Journal of Immunology, 2004, 173, 3878-3888.	0.8	28
51	Immunoglobulin genes in chronic lymphocytic leukemia: key to understanding the disease and improving risk stratification. Haematologica, 2017, 102, 968-971.	3.5	28
52	HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy. OncoImmunology, 2017, 6, e1219825.	4.6	28
53	Combined Patterns of IGHV Repertoire and Cytogenetic/Molecular Alterations in Monoclonal B Lymphocytosis versus Chronic Lymphocytic Leukemia. PLoS ONE, 2013, 8, e67751.	2.5	27
54	Chronic Lymphocytic Leukemia with Mutated IGHV4-34 Receptors: Shared and Distinct Immunogenetic Features and Clinical Outcomes. Clinical Cancer Research, 2017, 23, 5292-5301.	7.0	27

#	Article	IF	Citations
55	Cell lines generated from a chronic lymphocytic leukemia mouse model exhibit constitutive Btk and Akt signaling. Oncotarget, 2017, 8, 71981-71995.	1.8	27
56	Identification of checkpoints in human T-cell development using severe combined immunodeficiency stem cells. Journal of Allergy and Clinical Immunology, 2016, 137, 517-526.e3.	2.9	26
57	Next-Generation Sequencingâ€“Based Clonality Assessment of Ig Gene Rearrangements. Journal of Molecular Diagnostics, 2021, 23, 1105-1115.	2.8	25
58	Paediatric nodal marginal zone Bâ€cell lymphadenopathy of the neck: a Haemophilus influenzaeâ€driven immune disorder?. Journal of Pathology, 2015, 236, 302-314.	4.5	23
59	Phenotypic profile of expanded NK cells in chronic lymphoproliferative disorders: a surrogate marker for NK-cell clonality. Oncotarget, 2015, 6, 42938-42951.	1.8	23
60	Rapid Low-Cost Microarray-Based Genotyping for Genetic Screening in Primary Immunodeficiency. Frontiers in Immunology, 2020, 11, 614.	4.8	21
61	End stage renal disease patients have a skewed T cell receptor VÎ² repertoire. Immunity and Ageing, 2015, 12, 28.	4.2	20
62	High-risk subtypes of chronic lymphocytic leukemia are detectable as early as 16 years prior to diagnosis. Blood, 2022, 139, 1557-1563.	1.4	20
63	Accurate Quantification of T Cells by Measuring Loss of Germline T-Cell Receptor Loci with Generic Single Duplex Droplet Digital PCR Assays. Journal of Molecular Diagnostics, 2017, 19, 236-243.	2.8	19
64	End-Stage Renal Disease Causes Skewing in the TCR VÎ²-Repertoire Primarily within CD8+ T Cell Subsets. Frontiers in Immunology, 2017, 8, 1826.	4.8	19
65	<scp>CD</scp>38 expression in paediatric leukaemia and lymphoma: implications for antibody targeted therapy. British Journal of Haematology, 2018, 180, 292-296.	2.5	18
66	Quantitative Analysis of Minimal Residual Disease (MRD) Shows High Rates of Undetectable MRD after Fixed-Duration Chemotherapy-Free Treatment and Serves As Surrogate Marker for Progression-Free Survival: A Prospective Analysis of the Randomized CLL14 Trial. Blood, 2019, 134, 36-36.	1.4	18
67	The presence of CLL-associated stereotypic B cell receptors in the normal BCR repertoire from healthy individuals increases with age. Immunity and Ageing, 2019, 16, 22.	4.2	17
68	Anti-TRBC1 Antibody-Based Flow Cytometric Detection of T-Cell Clonality: Standardization of Sample Preparation and Diagnostic Implementation. Cancers, 2021, 13, 4379.	3.7	17
69	ATM mutations in major stereotyped subsets of chronic lymphocytic leukemia: enrichment in subset #2 is associated with markedly short telomeres. Haematologica, 2016, 101, e369-e373.	3.5	16
70	No improvement in long-term survival over time for chronic lymphocytic leukemia patients in stereotyped subsets #1 and #2 treated with chemo(immuno)therapy. Haematologica, 2018, 103, e158-e161.	3.5	16
71	Combined cellular and soluble mediator analysis for improved diagnosis of vitreoretinal lymphoma. Acta Ophthalmologica, 2019, 97, 626-632.	1.1	16
72	Severe COVID-19 Is Characterised by Perturbations in Plasma Amines Correlated with Immune Response Markers, and Linked to Inflammation and Oxidative Stress. Metabolites, 2022, 12, 618.	2.9	16

#	Article	IF	Citations
73	Spectrum of T-large granular lymphocyte lymphoproliferations: ranging from expanded activated effector T cells to T-cell leukaemia. British Journal of Haematology, 2003, 123, 561-562.	2.5	15
74	A very low thymus function identifies patients with substantial increased risk for long-term mortality after kidney transplantation. Immunity and Ageing, 2020, 17, 4.	4.2	15
75	Successive B-Cell Lymphomas Mostly Reflect Recurrences Rather Than Unrelated Primary Lymphomas. American Journal of Clinical Pathology, 2013, 140, 114-126.	0.7	14
76	Distinct and Overlapping Functions of TEC Kinase and BTK in B Cell Receptor Signaling. Journal of Immunology, 2017, 198, 3058-3068.	0.8	14
77	Plasma Oxylipins and Their Precursors Are Strongly Associated with COVID-19 Severity and with Immune Response Markers. Metabolites, 2022, 12, 619.	2.9	14
78	PCR-Based Analysis of Rearranged Immunoglobulin or T-Cell Receptor Genes by GeneScan Analysis or Heteroduplex Analysis for Clonality Assessment in Lymphoma Diagnostics. Methods in Molecular Biology, 2013, 971, 65-91.	0.9	13
79	Circulating T Cells of Patients with Nijmegen Breakage Syndrome Show Signs of Senescence. Journal of Clinical Immunology, 2017, 37, 133-142.	3.8	13
80	Blood cell counts and lymphocyte subsets of patients admitted during the COVIDâ€19 pandemic: a prospective cohort study. British Journal of Haematology, 2020, 190, e201-e204.	2.5	12
81	Recombination in the Human IGK Locus. Critical Reviews in Immunology, 2006, 26, 23-42.	0.5	12
82	High-Throughput immunogenetics for precision medicine in cancer. Seminars in Cancer Biology, 2022, 84, 80-88.	9.6	12
83	Lymphoma with multi-gene rearrangement on the level of immunoglobulin heavy chain, light chain, and T-cell receptor Î² chain. , 1998, 59, 99-100.		11
84	Dysregulated signaling, proliferation and apoptosis impact on the pathogenesis of TCRÎ³Î´+ T cell large granular lymphocyte leukemia. PLoS ONE, 2017, 12, e0175670.	2.5	11
85	Autologous Dendritic Cell Therapy in Mesothelioma Patients Enhances Frequencies of Peripheral CD4 T Cells Expressing HLA-DR, PD-1, or ICOS. Frontiers in Immunology, 2018, 9, 2034.	4.8	10
86	Reading the B-cell receptor immunome in chronic lymphocytic leukemia: revelations and applications. Experimental Hematology, 2021, 93, 14-24.	0.4	10
87	miR-181a is a novel player in the STAT3-mediated survival network of TCRÎ±Î²+ CD8+ T large granular lymphocyte leukemia. Leukemia, 2022, 36, 983-993.	7.2	10
88	T and B Cell Markers in Dried Blood Spots of Neonates with Congenital Cytomegalovirus Infection: B Cell Numbers at Birth Are Associated with Long-Term Outcomes. Journal of Immunology, 2017, 198, 102-109.	0.8	9
89	Flow cytometry shows added value in diagnosing lymphoma in brain biopsies. Cytometry Part B - Clinical Cytometry, 2018, 94, 928-934.	1.5	9
90	A New and Simple TRG Multiplex PCR Assay for Assessment of Tâ€cell Clonality: A Comparative Study from the EuroClonality Consortium. HemaSphere, 2019, 3, e255.	2.7	9

#	Article	IF	Citations
91	Vitreous proteomics, a gateway to improved understanding and stratification of diverse uveitis aetiologies. Acta Ophthalmologica, 2022, 100, 403-413.	1.1	9
92	Extensive longitudinal immune profiling reveals sustained innate immune activaton in COVID-19 patients with unfavorable outcome. European Cytokine Network, 2020, 31, 154-167.	2.0	9
93	Clonal antigen receptor gene PCR products outside the expected size range. Journal of Hematopathology, 2012, 5, 57-67.	0.4	8
94	Identification of Distinct Unmutated Chronic Lymphocytic Leukemia Subsets in Mice Based on Their T Cell Dependency. Frontiers in Immunology, 2018, 9, 1996.	4.8	8
95	Adult-Onset Autoimmune Enteropathy in an European Tertiary Referral Center. Clinical and Translational Gastroenterology, 2021, 12, e00387.	2.5	8
96	Multiple Immunoglobulin Îº Gene Rearrangements within a Single Clone Unraveled by Next-Generation Sequencingâ€“Based Clonality Assessment. Journal of Molecular Diagnostics, 2021, 23, 1097-1104.	2.8	8
97	Molecular diagnostics in lymphoma: why, when and how to apply. Diagnostic Histopathology, 2012, 18, 53-63.	0.4	6
98	Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation. Journal of Visualized Experiments, 2018, , .	0.3	6
99	PCR GeneScan and Heteroduplex Analysis of Rearranged Immunoglobulin or T-Cell Receptor Genes for Clonality Diagnostics in Suspect Lymphoproliferations. Methods in Molecular Biology, 2019, 1956, 77-103.	0.9	6
100	Overexpression of SH2-Containing Inositol Phosphatase Contributes to Chronic Lymphocytic Leukemia Survival. Journal of Immunology, 2020, 204, 360-374.	0.8	6
101	The miR-200c/141-ZEB2-TGFÎ² axis is aberrant in human T-cell prolymphocytic leukemia. Haematologica, 2022, 107, 143-153.	3.5	6
102	Immunoglobulin heavy variable somatic hyper mutation status in chronic lymphocytic leukaemia: on the threshold of a new era?. British Journal of Haematology, 2020, 189, 809-810.	2.5	6
103	Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989â€“2018. Blood Cancer Journal, 2022, 12, 72.	6.2	6
104	Low frequency of reverse transcription polymerase chain reaction-detectable chromosome aberrations in relapsed acute myeloid leukaemia: implications for detection of minimal residual disease. British Journal of Haematology, 2001, 113, 1076-1089.	2.5	5
105	Large granular lymphocyte cells and immune dysregulation diseases â€“ the chicken or the egg?. Haematologica, 2018, 103, 193-194.	3.5	5
106	Responsiveness of chronic lymphocytic leukemia cells to B-cell receptor stimulation is associated with low expression of regulatory molecules of the nuclear factor-ÎºB pathway. Haematologica, 2020, 105, 182-192.	3.5	5
107	TRB sequences targeting ORF1a/b are associated with disease severity in hospitalized COVIDâ€19 patients. Journal of Leukocyte Biology, 2021, , .	3.3	5
108	Consistent B Cell Receptor Immunoglobulin Features Between Siblings in Familial Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2021, 11, 740083.	2.8	5

#	Article	IF	Citations
109	Assessment of the Clonal Dynamics of Acquired Mutations in Patients (Pts) with Relapsed/Refractory Chronic Lymphocytic Leukemia (R/R CLL) Treated in the Randomized Phase 3 Murano Trial Supports Venetoclax-Rituximab (VenR) Fixed-Duration Combination Treatment (Tx). Blood, 2021, 138, 1548-1548.	1.4	5
110	Mediating effect of soluble B-cell activation immune markers on the association between anthropometric and lifestyle factors and lymphoma development. Scientific Reports, 2020, 10, 13814.	3.3	4
111	Euroclonality-NGS DNA Capture Panel for Integrated Analysis of IG/TR Rearrangements, Translocations, Copy Number and Sequence Variation in Lymphoproliferative Disorders. Blood, 2019, 134, 888-888.	1.4	4
112	Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features. Frontiers in Oncology, 2021, 11, 780085.	2.8	4
113	Validation of a Combined Transcriptome and T Cell Receptor Alpha/Beta (TRA/TRB) Repertoire Assay at the Single Cell Level for Paucicellular Samples. Frontiers in Immunology, 2020, 11, 1999.	4.8	3
114	Potential and pitfalls of whole transcriptome-based immunogenetic marker identification in acute lymphoblastic leukemia; a EuroMRD and EuroClonality-NGS Working Group study. Leukemia, 2021, 35, 924-928.	7.2	3
115	Transitioning T-Cell Clonality Testing to High-Throughput Sequencing. Journal of Molecular Diagnostics, 2021, 23, 781-783.	2.8	3
116	A novel digital PCR-based method to quantify (switched) B cells reveals the extent of allelic involvement in different recombination processes in the IGH locus. Molecular Immunology, 2022, 145, 109-123.	2.2	3
117	Clinicobiological characteristics and treatment efficacy of novel agents in chronic lymphocytic leukemia with IGLV3-21R110. Leukemia, 2022, , .	7.2	3
118	Immunoglobulin and T-cell receptor gene rearrangements. , 2006, , 210-234.		2
119	Capillary electrophoresis single-strand conformation analysis (CE-SSCA) for clonality detection in lymphoproliferative disorders. Journal of Hematopathology, 2012, 5, 83-89.	0.4	2
120	The EuroClonality website: information, education and support on clonality testing. Journal of Hematopathology, 2012, 5, 99-103.	0.4	2
121	Proteomic markers with prognostic impact on outcome of chronic lymphocytic leukemia patients under chemo-immunotherapy: results from the HOVON 109 study. Experimental Hematology, 2020, 89, 55-60.e6.	0.4	2
122	The variable biological signature of refractory cytopenia of childhood (RCC), a retrospective EWOG-MDS study. Leukemia Research, 2021, 108, 106652.	0.8	2
123	First Prospective Data on Impact of Minimal Residual Disease on Long-Term Clinical Outcomes after Venetoclax Plus Rituximab Versus Bendamustine Plus Rituximab: Phase III MURANO Study. Blood, 2018, 132, 185-185.	1.4	2
124	The Composition of the B Cell Receptor Repertoire In 7428 Cases of Chronic Lymphocytic Leukemia: One Third Stereotyped, Two Thirds Heterogeneous - What Does This Mean?. Blood, 2010, 116, 43-43.	1.4	2
125	A Model for Predicting Effect of Treatment on Progression-Free Survival Using Minimal Residual Disease As a Surrogate Endpoint in Chronic Lymphocytic Leukemia. Blood, 2015, 126, 720-720.	1.4	2
126	High, durable minimal residual disease negativity (MRDâ€“) with venetoclax + rituximab (VenR) in relapsed/refractory (R/R) CLL: MRD kinetics from phase 3 MURANO study.. Journal of Clinical Oncology, 2018, 36, 7508-7508.	1.6	2

#	Article	IF	Citations
127	T-Cell Receptor VÃŸ CDR3 Oligoclonality Frequently Occurs in Childhood Refractory Cytopenia and Severe Aplastic Anemia.. Blood, 2007, 110, 2449-2449.	1.4	2
128	Validation of the EuroClonality-NGS DNA capture panel as an integrated genomic tool for lymphoproliferative disorders. Blood Advances, 2021, 5, 3188-3198.	5.2	2
129	NGS-Based MRD Quantitation: An Alternative to qPCR Validated on a Large Consecutive Cohort of Children with ALL. Blood, 2021, 138, 1314-1314.	1.4	2
130	T and NK Cells in IL2RG-Deficient Patient 50 Years After Hematopoietic Stem Cell Transplantation. Journal of Clinical Immunology, 2022, 42, 1205-1222.	3.8	2
131	Molecular Monitoring of Lymphoma. , 2006, , 83-109.		1
132	Memento for interprofessional learning. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 755-756.	2.8	1
133	Flow cytometric analysis of the VÎ² repertoire in healthy controls. , 0, .		1
134	Library Preparation Is the Major Factor Affecting Differences in Results of Immunoglobulin Gene Rearrangements Detection on Two Major Next-Generation Sequencing Platforms. Blood, 2015, 126, 1411-1411.	1.4	1
135	Reappraising Immunoglobulin Repertoire Restrictions in Chronic Lymphocytic Leukemia: Focus on Major Stereotyped Subsets and Closely Related Satellites. Blood, 2016, 128, 4376-4376.	1.4	1
136	CALM-AF10 Positive T-ALLs Show a Pattern of Expression Similar to MLL-Translocated Acute Leukemias.. Blood, 2004, 104, 1108-1108.	1.4	1
137	Prognostic Significance of Molecular-Cytogenetic Abnormalities in Pediatric T-ALL Is Not Explained by Immunophenotypic Differences.. Blood, 2007, 110, 4220-4220.	1.4	1
138	Identification and Characterization of HLA Class I-Restricted MYD88 L265P-Derived Peptides As Tumor-Specific Targets for Immunotherapy. Blood, 2015, 126, 2750-2750.	1.4	1
139	Effect of fixed-duration venetoclax plus obinutuzumab (VenG) on progression-free survival (PFS), and rates and duration of minimal residual disease negativity (MRDâ€“) in previously untreated patients (pts) with chronic lymphocytic leukemia (CLL) and comorbidities.. Journal of Clinical Oncology, 2019, 37, 7502-7502.	1.6	1
140	CALM-AF10 and HOX11L2 Abnormalities Define Poor Prognostic Subgroups in Pediatric T-Cell Acute Lymphoblastic Leukemia.. Blood, 2005, 106, 3279-3279.	1.4	0
141	A New Subtype of T-Cell Acute Leukemia in Very Young Children Is Defined by a Translocation Targeting the C-MYB Oncogene, and a Specific Gene Expression Signature.. Blood, 2007, 110, 982-982.	1.4	0
142	Generation of T Cells from Human Embryonic Stem Cells.. Blood, 2008, 112, 1527-1527.	1.4	0
143	Deletion of the Protein Tyrosine Phosphatase Gene PTPN2 in T-Cell Acute Lymphoblastic Leukemia.. Blood, 2009, 114, 141-141.	1.4	0
144	Charting Unique Signatures of Somatic Hypermutation Amongst Chronic Lymphocytic Leukemia Patients Expressing IGHV4-34 Clonotypic B Cell Receptors. Blood, 2014, 124, 1969-1969.	1.4	0

#	Article	IF	Citations
145	The Integrated Immunological Signature of Refractory Cytopenia of Childhood (RCC). Blood, 2015, 126, 1657-1657.	1.4	0
146	Analytical Validation of Patient-Specific PCR-Based MRD Assessment for Use As a Primary Endpoint in CLL Clinical Trials. Blood, 2015, 126, 2924-2924.	1.4	0
147	ATM Mutations in Major Stereotyped CLL Subsets: Enrichment in Subset #2 is Associated with Unfavourable Outcome. Blood, 2015, 126, 1712-1712.	1.4	0
148	EGR2 Mutations in Chronic Lymphocytic Leukemia: A New Bad Player. Blood, 2015, 126, 4126-4126.	1.4	0
149	CLL with Mutated IGHV4-34 Antigen Receptors Is Clinically Heterogeneous: Antigen Receptor Stereotypy Makes the Difference. Blood, 2015, 126, 5263-5263.	1.4	0
150	Chronic Lymphocytic Leukemia (CLL) Clonal Growth Rate Is Slower Following Venetoclax-Rituximab (VenR): Results from a Minimal Residual Disease (MRD) Model from the Randomized Phase 3 Murano Trial. Blood, 2021, 138, 1551-1551.	1.4	0
151	Histopathological and immunological spectrum in response evaluation of talimogene laherparepvec treatment and correlation with durable response in patients with cutaneous melanoma. Melanoma Research, 2022, Publish Ahead of Print, .	1.2	0